In this session, US regulators are joined by regulators from several countries to discuss oncology-related international collaborations between regulatory authorities and a global framework for review of oncology products. Collaboration among international regulators may allow patients living with cancer to receive earlier access to products and future drug development may benefit by establishing greater uniformity of global standards of treatment, leading to the optimal design of clinical trials.